Benitec Biopharma Inc. (BNTC) Bundle
A Brief History of Benitec Biopharma Inc. (BNTC)
Company Founding and Overview
Benitec Biopharma Inc. was founded in 1995 and is headquartered in San Diego, California. The company specializes in the development of innovative therapeutics based on its proprietary DNA-directed RNA interference (ddRNAi) technology.
Key Milestones
- 1998: Benitec successfully licensed its ddRNAi technology to several companies.
- 2003: IPO launched on the Australian Stock Exchange (ASX), trading under the ticker BNT.
- 2016: Benitec announced a corporate restructuring to focus on its gene therapy programs.
- 2021: The company began its Phase 1 clinical trial for its lead product candidate, BB-301, aimed at treating dry age-related macular degeneration (AMD).
Financial Performance
For the fiscal year ended June 30, 2023, Benitec reported a net loss of $13.1 million, compared to a net loss of $12.5 million for the previous year. Total revenue for the fiscal year was $1.3 million, primarily from grants and collaborations, versus $1.1 million in the previous year.
| Year | Net Loss (in millions) | Total Revenue (in millions) |
|---|---|---|
| 2023 | $13.1 | $1.3 |
| 2022 | $12.5 | $1.1 |
Stock Performance
As of October 2023, Benitec's stock (BNTC) trades on the NASDAQ. The share price has seen significant fluctuations, with a 52-week range of $0.15 to $1.00. The market capitalization is approximately $20 million.
Strategic Partnerships and Collaborations
Benitec has engaged in various collaborations to advance its research and development. Notable partnerships include:
- 2019: Partnership with Regeneron Pharmaceuticals for the development of novel therapies.
- 2020: Collaboration with Wuxi AppTec to enhance its clinical development capabilities.
Current Research and Development Focus
The current focus of Benitec revolves around its lead candidate, BB-301, which is targeting lower frequencies of viral infections and genetic diseases. The company is also exploring additional applications of its ddRNAi technology in oncology and rare diseases.
Recent Developments
In September 2023, Benitec announced the completion of patient enrollment for the Phase 1 clinical trial of BB-301. The trial aims to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with dry AMD.
Future Outlook
Looking forward, Benitec plans to expand its pipeline with new product candidates based on ddRNAi technology while continuing to advance clinical trials for BB-301. The company aims to leverage its partnerships to accelerate development and commercialization efforts.
A Who Owns Benitec Biopharma Inc. (BNTC)
Current Ownership Structure
Benitec Biopharma Inc. (ticker: BNTC) has a diverse set of shareholders, including institutional investors and retail shareholders. As of the latest reports, the ownership percentages are as follows:
| Shareholder Type | Percentage Owned |
|---|---|
| Institutional Investors | 25.3% |
| Retail Investors | 42.1% |
| Insider Ownership | 32.6% |
Major Shareholders
The top shareholders of Benitec Biopharma as of the most recent filings are:
| Shareholder Name | Shares Owned | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 1,200,000 | 15.5% |
| Vanguard Group Inc. | 900,000 | 11.7% |
| Dr. Peter French (CEO) | 500,000 | 6.4% |
| Other Institutional Holders | 600,000 | 7.8% |
Recent Share Price and Market Capitalization
The latest share price of Benitec Biopharma is approximately $1.20. This translates into a market capitalization of:
Market Capitalization = Share Price Total Shares Outstanding
Total Shares Outstanding: 7,743,000
Thus, the market capitalization is approximately $9.28 million.
Recent Developments in Shareholding
In the last financial quarter, insider trading activities included:
| Insider Name | Transaction Type | Shares Traded | Date |
|---|---|---|---|
| Dr. Peter French | buy | 50,000 | August 15, 2023 |
| Robert E. McCaffrey | sell | 30,000 | September 10, 2023 |
Performance and Future Outlook
As of the latest earnings report, Benitec Biopharma reported revenues of:
- Quarterly Revenue: $1.5 million
- Net Loss for Quarter: $2.0 million
- Cash Reserves: $3.2 million
Future projections indicate a focus on advancing their therapeutic pipeline, which may impact ownership dynamics if additional funding rounds are initiated or if substantial stakeholders decide to increase their positions.
Benitec Biopharma Inc. (BNTC) Mission Statement
Company Overview
Benitec Biopharma Inc. is a biotechnology company that specializes in developing innovative therapies for chronic diseases, including viral infections, cancer, and genetic disorders. The company's pioneering approach harnesses gene silencing technologies to provide targeted treatment options.
Mission Statement
The mission of Benitec Biopharma Inc. is to leverage its proprietary technology to develop transformative genetic medicines through leveraging gene silencing to revolutionize treatment paradigms for patients with significant unmet medical needs, thereby enhancing the quality of life and extending life expectancy.
Focus Areas
- Chronic Diseases
- Viral Infections
- Cancer
- Genetic Disorders
Recent Financial Performance
As of the fiscal year ending June 30, 2023, Benitec reported total revenue of $1.2 million and a net loss of $7.4 million. The company's research and development expenses for the year were $5.5 million, reflecting a commitment to advancing its pipeline of therapeutic candidates.
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | $1.2 million |
| Net Loss | $7.4 million |
| Research and Development Expenses | $5.5 million |
| Cash and Cash Equivalents (as of June 30, 2023) | $10.0 million |
Technological Innovations
Benitec's proprietary technology, known as ddRNAi (DNA-directed RNA interference), is designed to silence genes associated with disease. This technology presents a unique opportunity to target the root causes of various conditions, potentially offering more effective therapies compared to traditional approaches.
Pipeline Overview
The current pipeline includes several promising candidates in various stages of development:
| Product Candidate | Indication | Development Stage |
|---|---|---|
| BB-301 | Ocular Disease | Phase 1 |
| BB-401 | Viral Hepatitis | Preclinical |
| BB-501 | Oncology | Phase 1 |
Strategic Partnerships
Benitec has established strategic collaborations with multiple organizations to enhance its research capabilities and market reach. Notably, partnerships with academic institutions and pharmaceutical companies are integral to its mission of delivering advanced therapeutic solutions.
Market Outlook
The global gene therapy market is projected to grow from $3.1 billion in 2022 to $14.5 billion by 2028, at a CAGR of 30.5%. This growth underscores the significant opportunity for Benitec Biopharma Inc. to capitalize on its innovative therapeutics in the expanding biotechnology sector.
Challenges and Risks
Despite the potential, Benitec faces several challenges, including:
- Regulatory hurdles
- Clinical trial uncertainties
- Competitive landscape
Conclusion
Benitec Biopharma Inc. remains committed to its mission of creating impactful gene therapies that address critical health issues. Its focus on innovation, strategic partnerships, and responsiveness to market dynamics positions the company for future growth and success.
How Benitec Biopharma Inc. (BNTC) Works
Overview of Benitec Biopharma Inc.
Overview of Benitec Biopharma Inc.
Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company focused on developing innovative therapeutics based on its proprietary gene-silencing technology known as DNA-directed RNA interference (ddRNAi). The company's primary aim is to address severe diseases caused by genetic mutations and viral infections.
Business Model and Strategy
The business model of Benitec Biopharma revolves around the following key strategies:
- Utilization of the ddRNAi platform to develop therapies targeting both genetic and infectious diseases.
- Collaboration with partners in academia and industry to enhance research and development efforts.
- Leveraging intellectual property for strategic partnerships and licensing agreements.
Key Products and Pipeline
Benitec's pipeline includes several promising therapeutic candidates:
- BB-301: for the treatment of Wet Age-Related Macular Degeneration (AMD).
- BB-401: targeting Hepatitis B virus.
- BB-101: for Ocular diseases.
Financial Performance
As of the latest financial report for the fiscal year 2022, Benitec Biopharma reported:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue | $0 |
| Net Loss | ($16.5 million) |
| Total Assets | $9.5 million |
| Total Liabilities | $5.8 million |
| Cash and Cash Equivalents | $7.0 million |
Recent Developments
Benitec has made several advancements in its operations, including:
- Announced positive results from early-stage clinical trials in 2023.
- Secured a partnership with a leading pharmaceutical company for co-development efforts.
- Received FDA clearance for investigational new drug applications (IND) for BB-401 in 2023.
Market and Competitive Landscape
Benitec operates in the competitive biotechnology market, with key competitors including:
- Alnylam Pharmaceuticals, Inc.
- Moderna, Inc.
- Ionis Pharmaceuticals, Inc.
The global market for RNA interference therapeutics is projected to reach approximately $5.5 billion by 2025, presenting significant growth opportunities.
Stock Performance and Valuation
As of October 2023, the stock price of Benitec Biopharma Inc. is approximately $0.31 per share, with a market capitalization of around $26 million. The 52-week range for BNTC stock is $0.25 to $0.65.
Conclusion of Financial Health
The financial health of Benitec Biopharma can be summarized as follows:
| Metric | Value |
|---|---|
| Current Ratio | 1.55 |
| Debt to Equity Ratio | 0.61 |
| Operating Cash Flow | ($10.1 million) |
| Burn Rate | Approximately $1.4 million per quarter |
Future Outlook
The future outlook for Benitec includes anticipation of upcoming clinical trial phases, potential partnerships, and the strategic goal to advance its ddRNAi technology towards commercialization. The company aims to raise additional capital to fund ongoing research and development.
How Benitec Biopharma Inc. (BNTC) Makes Money
Revenue Streams
Benitec Biopharma Inc. (BNTC) primarily generates revenue through its innovative biotechnology products and collaborations in the field of gene therapy. The company is focused on developing therapies for chronic diseases, specifically targeting areas of unmet medical need.
Product Pipeline and Development
Benitec has a diverse pipeline that includes lead product candidates like BB-301, aimed at treating wet age-related macular degeneration (AMD). The success of these products is pivotal for revenue realization.
Collaborations and Partnerships
Collaborative partnerships are a significant source of revenue for Benitec. Recent collaborations include:
- Collaboration with Takeda Pharmaceuticals for gene therapy development and commercialization.
- Partnership with The University of Queensland for research and development of gene therapies.
Financial Performance
As of the fiscal year ending June 30, 2023, Benitec reported the following financial metrics:
| Financial Metrics | FY 2023 Amount (USD) |
|---|---|
| Total Revenue | $3.5 million |
| Net Income (Loss) | $(8.2 million) |
| Total Assets | $45 million |
| Total Liabilities | $22 million |
| Cash and Cash Equivalents | $12 million |
Grants and Funding
Benitec has successfully secured various grants to support its research initiatives, amounting to approximately $1 million per year. These grants come from:
- The National Institutes of Health (NIH)
- Private Foundations
Market Potential
The market potential for Benitec's product candidates is substantial, particularly in the fields of ophthalmology and oncology, with projected market sizes:
| Therapy Area | Projected Market Size (USD, by 2028) |
|---|---|
| Ophthalmology | $16 billion |
| Oncology | $80 billion |
Stock Performance
As of October 2023, the stock price of BNTC is approximately $0.90 per share, with a market capitalization of around $50 million. The company's stock performance is closely monitored by investors and analysts due to its potential in the biotech sector.
Future Outlook
With a focus on advancing clinical trials and expanding therapeutic applications, Benitec aims to enhance its revenue streams through successful product launches. Investment in R&D is projected to increase, with an estimated budget allocation of $10 million for the upcoming fiscal year.
Summary of Financial Metrics
| Year | Total Revenue (USD) | Net Income (Loss) (USD) | Total Assets (USD) | Cash Reserves (USD) |
|---|---|---|---|---|
| 2023 | $3.5 million | $(8.2 million) | $45 million | $12 million |
| 2022 | $5.0 million | $(7.0 million) | $40 million | $10 million |
Benitec Biopharma Inc. (BNTC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support